UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934
Date of Report (Date of earliest reported event): March 17, 2010
GEOPHARMA, INC.
(Exact name of registrant as specified in charter)
| | | | |
Florida | | 001-16185 | | 59-2600232 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | |
6950 Bryan Dairy Road, Largo, Florida | | 33777 |
(Address of principal executive offices) | | (Zip Code) |
Registrant's telephone number, including area code: (727) 544-8866
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule
On March 17, 2010, GeoPharma, Inc. received a letter from The Nasdaq Stock Market regarding the Company's noncompliance with Listing Rule 5550(a)(2), as related to the maintenance of the $1 bid price of the Company's common stock and Listing Rule 5810(c)(3)(A), as related to the 180 calendar day extension granted.
The Company plans on requesting a hearing as provided for in those Listing Rules. The deadline for the request for hearing is 4:00 pm Eastern Time on March 23, 2010.
A copy of the letter is attached as Exhibit 99.1 hereto.
ITEM 9.01. | Financial Statements and Exhibits. |
(d) Exhibits. The following documents are filed as exhibits to this report:
99.1 Nasdaq Letter
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorize
| | |
| | GEOPHARMA, INC. |
| |
Date: March 22, 2010 | | /s/ Mihir K. Taneja |
| | Mihir K. Taneja, |
| | Chief Executive Officer |
| |
| | /s/ Carol Dore-Falcone |
| | Carol Dore-Falcone, |
| | Senior Vice President and Chief Financial Officer |
3
